Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy

This study has been terminated.
(Development of tasquinimod in prostate cancer discontinued)
Sponsor:
Information provided by (Responsible Party):
Ipsen
ClinicalTrials.gov Identifier:
NCT01732549
First received: October 24, 2012
Last updated: August 9, 2016
Last verified: August 2016
  Purpose
The purpose of this study is to confirm that tasquinimod used as maintenance therapy is active and tolerable in patients with metastatic castrate-resistant prostate cancer not progressing after a first chemotherapy with docetaxel.

Condition Intervention Phase
Metastatic Castrate Resistant Prostate Cancer
Drug: Tasquinimod
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-Blind, Placebo-Controlled Proof Of Concept Study Of Maintenance Therapy With Tasquinimod In Patients With Metastatic Castrate-Resistant Prostate Cancer Who Are Not Progressing After A First Line Docetaxel Based Chemotherapy

Resource links provided by NLM:


Further study details as provided by Ipsen:

Primary Outcome Measures:
  • Time to Radiological Progression Free Survival [PFS] [ Time Frame: Every 8 weeks until disease progression documentation (approximately up to 2.5 years) ] [ Designated as safety issue: No ]

    The time from the date of randomisation to the date of radiological progression or death due to any cause.

    Radiological progression was defined

    - Using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for soft tissue lesions (Eisenhauer, EJC 2009), as at least a 20% relative and a 5 mm absolute increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters recorded on study (including Screening or the appearance of one or more new lesions) for target Lesions.

    Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions

    - Using Prostate Cancer Clinical Working Group in March 2008 (PCWG2) criteria for bone lesions (Scher, JCO 2008). Progression was defined as appearance of 2 or more bone lesions.



Secondary Outcome Measures:
  • Overall Survival Based on Number of Subjects Who Died [ Time Frame: Every 3 months after study treatment stop until death (approximately up to 2.5 years) ] [ Designated as safety issue: No ]

    Overall survival is defined as the time from randomisation to death due to any cause.

    The number of participants who died is presented since the Median was not reached for this assessment.

    Tasquinimod: Patients censored = 63, Patients at risk (t=0) = 71 Placebo: Patients censored = 67, Patients at risk (t=0) = 73


  • Time to Progression Free Survival [PFS] on Next-line Therapy (PFS 2) [ Time Frame: Every 3 months after study treatment stop (follow-up) until progression under the next line therapy (approximately up to 2.5 years) ] [ Designated as safety issue: No ]

    The time from the date of randomisation to the date of radiological progression free survival [PFS] on next-line therapy (PFS 2) or death due to any cause.

    Radiological progression was defined

    - Using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for soft tissue lesions (Eisenhauer, EJC 2009), as at least a 20% relative and a 5 mm absolute increase in the sum of diameters of target lesions, taking as reference the smallest sum of diameters recorded on study (including Screening or the appearance of one or more new lesions) for target Lesions.

    Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions

    - Using Prostate Cancer Clinical Working Group in March 2008 (PCWG2) criteria for bone lesions (Scher, JCO 2008). Progression was defined as appearance of 2 or more bone lesions.


  • Symptomatic PFS Based on Number of Subjects Who Had Symptomatic Progression or Death [ Time Frame: Every 8 weeks until symptomatic or radiological progression documentation (approximately up to 2.5 years) ] [ Designated as safety issue: No ]

    Symptomatic PFS is defined as the time from the date of randomisation to the date of symptomatic progression or death due to prostate cancer, whichever occurs first [symptomatic progression as assessed by Brief Pain Inventory (BPI) and analgesic use].

    Symptomatic progression was defined by the occurrence of pain with documented disease, skeleton related adverse events.

    The median symptomatic PFS for placebo and tasquinimod groups was not reached.

    Tasquinimod: Patients censored = 48, Patients at risk (t=0) = 71 Placebo: Patients censored = 54, Patients at risk (t=0) = 73


  • Time to Further Anticancer Treatment for Prostate Cancer [ Time Frame: Every 3 months after study treatment stop until further anticancer therapy for prostate cancer (approximately up to 2.5 years) ] [ Designated as safety issue: No ]
    Time from randomisation to further treatment for prostate cancer

  • Time to Deterioration in Functional Assessment of Cancer Therapy - Prostate (FACT-P) [ Time Frame: Up to End of Study visit (approximately up to 2.5 years) ] [ Designated as safety issue: No ]

    End of Study visit (within 14 days of last dose of study treatment)

    Impact of tasquinimod on health related quality of life (QoL) - Analysis of time to deterioration in FACT-P

    The FACT-P measurement system is a validated collection of health related quality of life (HRQOL) questionnaires used to assess HRQOL in men with prostate cancer. It is appropriate for use with patients with any form of cancer and extensions of it have been used and validated in other chronic illness condition. The FACT-P is a self-administered 39-item scale comprising five domains: physical well-being, social/family well-being, functional well-being, emotional well-being and additional concerns. The individual subscale scores range from 0 to a high between 24 and 48 and the total score ranges between 0 and 156, with higher scores representing better Quality of Life (QoL)


  • Change From Baseline of EuroQol-5 Dimension QoL Instrument (EQ-5D) VAS Score [ Time Frame: Baseline and End-of-study Visit (approximately up to 2.5 years) ] [ Designated as safety issue: No ]

    Baseline is defined as last measurement collected prior to the first dose of study drug. End of Study visit (within 14 days of last dose of study treatment)

    The EQ-5D, a 5-item scale useful in health resource utilisation and cost comparisons between treatment groups designed for self-completion by patients consists of two pages [EQ-5 descriptive system and EQ Visual Analogue Scale(VAS)]. The EQ-5 descriptive system comprises five dimensions: mobility, self care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, severe problems. The EQ-VAS records the respondent's self-rated health on a vertical VAS. The respondents are asked to mark health status on the day of the interview on a 10cm vertical scale with end points of 0 to100. There are notes at the both ends of the scale that the bottom rate(0) corresponds to "the worst health you can imagine", and the highest rate(100) corresponds to "the best health you can imagine"


  • Safety Profile of Tasquinimod [ Time Frame: At regular intervals during the study treatment period and every 3 months during the follow-up until death (approximately up to 2.5 years) ] [ Designated as safety issue: Yes ]
    Number of subjects reporting adverse events


Enrollment: 144
Study Start Date: January 2013
Study Completion Date: May 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tasquinimod
1 capsule daily, taken orally with water and food (0.25 mg initially then dose escalated to 0.5 mg or 1 mg per day) until disease progression or toxicity or patient's willingness to stop.
Drug: Tasquinimod
A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
Placebo Comparator: Placebo
1 capsule daily, taken orally with water and food until disease progression or toxicity or patient's willingness to stop.
Drug: Placebo
Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically documented prostate cancer with evidence of metastatic disease on radiological evaluation, with or without symptoms (defined according to the BPI scale, with use of analgesics or narcotics)
  • Has received a first line docetaxel based chemotherapy (as a monotherapy) every 3 weeks schedule of administration with corticosteroids for a minimum of 6 cycles with a cumulative dose ≥360 mg/m2. Any combination with investigational or non investigational agent is prohibited
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Docetaxel-related adverse effects must have been resolved to NCI-CTCAE v4.03 (Common Toxicity Criteria for Adverse Effects) Grade ≤1. Chemotherapy-induced alopecia and Grade 2 peripheral neuropathy are allowed
  • No progressive disease at the end of docetaxel treatment defined according to RECIST criteria, no new lesion(s) assessed by bone scan and no elevated prostate specific antigen (PSA) for the three last tests with PSA3≤PSA2≤PSA1. The time between each PSA test should be preferably at least 14 days, however, a minimum of 7 days is acceptable.

Note: PSA value can be rounded to the nearest whole number if PSA>10 ng/mL. If the PSA3 value is above the PSA2, a fourth PSA test will be performed. The PSA4 value should be below or equal to PSA2

  • Last dose of docetaxel administered between 21 and 42 days before randomisation
  • Chemical or surgical castration verified by levels of serum testosterone ≤50 ng/dL (1.75 nmol/L)

Exclusion Criteria:

  • Has concurrent use of other anticancer agents or treatments, with the following exceptions: ongoing treatment with luteinising hormone-releasing hormone agonists or antagonists, denosumab or bisphosphonate (e.g., zoledronic acid) is permitted if started ≥4 weeks prior to Screening. Ongoing treatment should be kept at a stable dose regimen
  • Has ongoing treatment with warfarin
  • Had prior radiation therapy since starting docetaxel. Exceptions may be made for palliative non-myelosuppressive radiation therapy administered more than 2 weeks prior to randomisation
  • Had prior strontium, samarium or radium therapy or prior treatment with tasquinimod, or any agents with antiangiogenic properties
  • Has ongoing treatment with corticosteroids at >10 mg/day prednisolone equivalent
  • Has prostate cancer pain that warrants the initiation of radiotherapy or chemotherapy
  • Has known brain or epidural metastases. Patients with previous medullary cord compression without any neurological deficit could be included
  • Has a history of other malignancies, except adequately treated non-melanoma skin cancer or other solid tumours curatively treated, without evidence of disease for >5 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01732549

  Show 58 Study Locations
Sponsors and Collaborators
Ipsen
Investigators
Study Director: Nathalie Germann, MD Ipsen
  More Information

Responsible Party: Ipsen
ClinicalTrials.gov Identifier: NCT01732549     History of Changes
Other Study ID Numbers: 8-55-58102-002 
Study First Received: October 24, 2012
Results First Received: April 29, 2016
Last Updated: August 9, 2016
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products
Czech Republic: State Institute for Drug Control
Denmark: Danish Medicines Agency
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Germany: Federal Institute for Drugs and Medical Devices
Hungary: National Institute of Pharmacy
Italy: The Italian Medicines Agency
Lithuania: State Medicine Control Agency - Ministry of Health
Spain: Agencia Española de Medicamentos y Productos Sanitarios
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Docetaxel
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on December 08, 2016